Current financial headlines
Sharemaestro Newsreel
Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.
- Showing
- 1765–1800
- Headlines
- 43219
- Sources here
- 11
- Companies here
- 31
Current section
United States Healthcare news
Chronological news
Earlier headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Intuitive Surgical (ISRG) Is Facing Fresh Competition In U.S. Surgical Robotics
Intuitive Surgical (ISRG) is facing new competition in the U.S. surgical robotics market as Johnson & Johnson's Ottava system received FDA authorization. Ottava's space-saving design and integration with J&J's existing surgical tools pose a direct challenge to Intuitive Surgical's da Vinci systems, potentially impacting …
ISRG
main company
Sharemaestro market context
Price below Trend Line
52 weeks -17.1% · Next-week setup negative 41.3%
NRx Pharmaceuticals (NRXP) grows clinic revenue, flags going concern risk
NRx Pharmaceuticals reported its Q2 2026 results, showing significant growth in net patient service revenue to $1.1 million for the quarter and $2.2 million for the first six months, primarily through its HOPE subsidiary's acquired Florida behavioral health clinics. Despite this new revenue stream …
NRXP
main company
Sharemaestro market context
Trend signal active
52 weeks +23.9% · Next-week setup negative 40.1%
Lynx1 Capital Management (IBIO) corrects 5.4% iBio stake including 2.8M warrant shares
Lynx1 Capital Management LP and Weston Nichols have filed an amended Schedule 13G for iBio, Inc. (IBIO), correcting their reported beneficial ownership to include 2,807,016 shares of common stock issuable upon exercise of Series F warrants. This represents a 5.4% stake in iBio, based …
IBIO
main company
Sharemaestro market context
Price below Trend Line
52 weeks +80.8%
GT Biopharma (NASDAQ: GTBP) wins approval for reverse split and share plan changes
GT Biopharma shareholders approved a reverse stock split, ranging from 1-for-10 to 1-for-30, and a reduction in authorized shares to 25,000,000 common and 1,500,000 preferred shares. They also approved a 3,500,000-share increase to the 2022 Omnibus Incentive Plan and an evergreen provision for automatic …
GTBP
main company
Sharemaestro market context
Price below Trend Line
52 weeks -73.3% · Next-week setup negative 42.9%
InspireMD (NSPR) grows revenue 56% but flags going concern and Nasdaq risk
InspireMD, Inc. reported increased revenues for the first half of 2026, up 56.3% to $5.17 million, driven by U.S. CGuard Prime sales and international growth, despite a voluntary recall of CGuard Prime impacting quarterly revenue and gross margin. The company posted a significant net …
NSPR
main company
Sharemaestro market context
Price below Trend Line
52 weeks -58.6% · Next-week setup negative 42.7%
Kura Oncology (KURA) investors report up to 9.7% beneficial ownership stakes
Montanova Capital, LLC, Averill Master Fund, Ltd., and Aaron Cowen have reported significant beneficial ownership stakes in Kura Oncology, Inc. Montanova Capital and Aaron Cowen each own 9.7% of the common stock, while Averill Master Fund holds 8.8%. The reported shares are directly owned …
KURA
main company
Sharemaestro market context
Trend signal active
52 weeks +42.0%
Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock
Vivo Opportunity entities, including Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P., have reported beneficial ownership of 9.99% of Pasithea Therapeutics (KTTA) common stock. These holdings comprise a mix of common shares and pre-funded warrants, which include provisions to prevent ownership …
KTTA
main company
Sharemaestro market context
Price below Trend Line
52 weeks -33.0% · Next-week setup negative 42.6%
Femasys (NASDAQ: FEMY) cuts net loss and secures $30M private funding
Femasys Inc. (NASDAQ: FEMY) reported a narrowed net loss of $3.6 million for the first half of 2026, significantly down from $10.5 million in 2025, largely due to non-cash gains from reclassifying conversion options and warrant liabilities. The company secured approximately $30 million in …
FEMY
main company
Sharemaestro market context
Price below Trend Line
52 weeks -79.9% · Next-week setup negative 40.5%
LB Pharmaceuticals (LBRX) investor group reports 5.0% beneficial stake in 13G/A
TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have reported a beneficial ownership of 5.0% in LB Pharmaceuticals Inc. (LBRX), totaling 1,447,310 shares, through an amended Schedule 13G filing. This ownership percentage is based on 28,676,652 shares outstanding as …
LBRX
main company
Sharemaestro market context
Trend signal active
49 weeks +184.4% · Next-week setup positive 67.7%
Femasys Reports $331,827 Q2 Revenue and $4.47 Million Net Loss
Femasys (FEMY) reported a Q2 2026 revenue of $331,827, an 18.9% decrease year-over-year, and a net loss of $4.47 million. Despite the revenue decline, the company completed a $30 million private placement and launched FemaSeed Complete, while insiders made multiple stock purchases, indicating confidence …
FEMY
main company
Sharemaestro market context
Price below Trend Line
52 weeks -79.9% · Next-week setup negative 40.5%
Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even More
The past couple of years have been volatile for Vertex Pharmaceuticals (NASDAQ: VRTX). Between clinical setbacks and worse-than-expected financial results, the company has sometimes disappointed investors. However, Vertex has always bounced back, and it recently hit a new all-time high, though it has since …
Sharemaestro market context Trend signal active 52 weeks +28.0%NeoGenomics (NEO) stake tops 8% for First Light’s Mathew Arens
Mathew P. Arens and First Light Asset Management, LLC have reported their beneficial ownership in NeoGenomics, Inc. through a Schedule 13G/A filing. Arens beneficially owns 8.37% of NeoGenomics' common stock, totaling 10,759,586 shares, which includes holdings through First Light, direct shares, and a joint …
NEO
main company
Sharemaestro market context
Trend signal active
52 weeks +141.3% · Next-week setup negative 40.8%
Nephros (NEPH) director Arthur Amron granted 2,418 shares, holds 140,874
Nephros Inc. director Arthur H. Amron was granted 2,418 shares of Common Stock on August 12, 2026, as compensation for his board service, increasing his direct holdings to 140,874 shares. He also holds stock options for 7,323 shares fully vested at an exercise price …
NEPH
main company
Sharemaestro market context
Price above Trend Line
52 weeks +10.6%
NewAmsterdam Pharma (NAMS) hires Robert Gunning as new principal accounting officer
NewAmsterdam Pharma Company N.V. (NAMS) has appointed Robert W. Gunning, 55, as its new principal accounting officer, effective August 10, 2026. Gunning will receive an annual base salary of $375,000, a target annual performance bonus of 30% of his base salary, and equity awards …
NAMS
main company
Sharemaestro market context
Price below Trend Line
52 weeks +7.9%
NewAmsterdam Pharma (NAMS) outlines Douglas Kling separation and advisory deal
NewAmsterdam Pharma (NAMS) has filed an amendment detailing the separation and advisory agreements with its former Chief Operating Officer, Douglas Kling, who resigned effective August 14, 2026. Kling's unvested stock options and restricted stock units will be canceled, except for those tied to continued …
NAMS
main company
Sharemaestro market context
Price below Trend Line
52 weeks +7.9%